<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921372</url>
  </required_header>
  <id_info>
    <org_study_id>IsometricProtocol2</org_study_id>
    <nct_id>NCT03921372</nct_id>
  </id_info>
  <brief_title>Isometric Exercise in NTG</brief_title>
  <official_title>Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Patients With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augenabteilung Allgemeines Krankenhaus Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augenabteilung Allgemeines Krankenhaus Linz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing&#xD;
      evidence that dysfunction of ocular microcirculation in the optic nerve influences the&#xD;
      progression of glaucoma. It has been shown that flicker light-induced vasodilatation of&#xD;
      retinal veins is diminished in patients with glaucoma. Also previous studies indicate that&#xD;
      the blood flow autoregulation is impaired in patients with glaucoma. Therefor the ocular&#xD;
      perfusion pressure can not be maintained stable during changes of the systemic arterial blood&#xD;
      pressure. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular&#xD;
      perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the&#xD;
      optic disc in Japanese glaucoma patients.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
      To assess the changes in LSFG parameters in patients with normal tension glaucoma, compared&#xD;
      to healthy subjects during flicker light stimulation and isometric exercises.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean blur rate</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Mean Blur Ratio</condition>
  <arm_group>
    <arm_group_label>Normal Tension Glaucoma (NTG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diagnosed NTG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no sign of glaucoma, Age and sex matched</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Isometric exercise</intervention_name>
    <description>Squatting for 5 minutes</description>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma (NTG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Study population: patients with normal tension glaucoma&#xD;
&#xD;
               -  Caucasian men and women aged over 50 years&#xD;
&#xD;
               -  Subject is generally healthy with no current significant or a history of a&#xD;
                  significant neurological, cardiovascular, pulmonary (including asthma), hepatic,&#xD;
                  metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined&#xD;
                  by the investigator's clinical judgment through collection of medical history and&#xD;
                  performance of a physical examination. A significant disorder is defined as a&#xD;
                  disease or medical condition associated with impaired health status, requiring&#xD;
                  regular or current medical treatment and/or follow up. For the purposes of this&#xD;
                  study, an investigator may classify a medical condition as a nonsignificant&#xD;
                  disorder despite the fact that the subject receives treatment. Subjects having&#xD;
                  controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or&#xD;
                  90-99 mmHg diastolic) are eligible for participation in this study&#xD;
&#xD;
               -  Normal open angle in a gonioscopic examination&#xD;
&#xD;
               -  Presence of glaucomatous optic disc changes in biomicroscopy and&#xD;
&#xD;
               -  Visual field defects in at least two visual field examinations (Reliability&#xD;
                  criteria: fixation errors &lt; 20%, false positives &lt; 15%, and false negatives &lt;&#xD;
                  33%) Or&#xD;
&#xD;
               -  Abnormal circumpapillary retinal nerve fiber layer thinning (RNFL evaluated by&#xD;
                  OCT)&#xD;
&#xD;
          2. Control group&#xD;
&#xD;
               -  Men and women aged over 18 years&#xD;
&#xD;
               -  Subject is generally healthy with no current significant or a history of a&#xD;
                  significant neurological, cardiovascular, pulmonary (including asthma), hepatic,&#xD;
                  metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined&#xD;
                  by the investigator's clinical judgment through collection of medical history and&#xD;
                  performance of a physical examination. A significant disorder is defined as a&#xD;
                  disease or medical condition associated with impaired health status, requiring&#xD;
                  regular or current medical treatment and/or follow up. For the purposes of this&#xD;
                  study, an investigator may classify a medical condition as a nonsignificant&#xD;
                  disorder despite the fact that the subject receives treatment. Subjects having&#xD;
                  controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or&#xD;
                  90-99 mmHg diastolic) are eligible for participation in this study&#xD;
&#xD;
               -  Baseline IOP in both eyes below 21 mm Hg&#xD;
&#xD;
               -  Normal findings in slitlamp and funduscopic examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a) Study population: patients with normal tension glaucoma&#xD;
&#xD;
          -  History of ocular or systemic disease causing optic nerve damage&#xD;
&#xD;
          -  History of IOP greater than 21 mm Hg (corrected by CCT)&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks preceding the study&#xD;
&#xD;
          -  Ocular surgery (including intravitreal injection) during the 3 months preceding the&#xD;
             study&#xD;
&#xD;
          -  Ametropia &gt; 6 Dpt&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  pre- or perimenopausal women&#xD;
&#xD;
          -  Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements&#xD;
             (e.g. optic nerve head drusen, tilted disc, etc.)&#xD;
&#xD;
          -  Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II&#xD;
             grading &gt; 2, posterior capsule opacification) or the vitreous (e.g. vitreous&#xD;
             haemorrhage, asteroid hyalosis)&#xD;
&#xD;
          -  Patients who are not able to cooperate or with insufficient ability to fixate (tremor,&#xD;
             nystagmus)&#xD;
&#xD;
          -  Blood donation in the 3 weeks preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Ocular infection or clinically significant inflammation&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
&#xD;
             b) Control group&#xD;
&#xD;
          -  Abnormal RNFL&#xD;
&#xD;
          -  Visual field defects&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks preceding the study&#xD;
&#xD;
          -  Ocular surgery (including intravitreal injection) during the 3 months preceding the&#xD;
             study&#xD;
&#xD;
          -  Ametropia &gt; 6 Dpt&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements&#xD;
             (e.g. optic nerve head drusen, tilted disc, etc.)&#xD;
&#xD;
          -  Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II&#xD;
             grading &gt; 2, posterior capsule opacification) or the vitreous (e.g. vitreous&#xD;
             haemorrhage, asteroid hyalosis)&#xD;
&#xD;
          -  Patients who are not able to cooperate or with insufficient ability to fixate (tremor,&#xD;
             nystagmus)&#xD;
&#xD;
          -  Blood donation in the 3 weeks preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Ocular infection or clinically significant inflammation&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Bolz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allgemeines Krankenhaus Linz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKh Linz</name>
      <address>
        <city>Linz</city>
        <state>Ober√∂sterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augenabteilung Allgemeines Krankenhaus Linz</investigator_affiliation>
    <investigator_full_name>Matthias Bolz</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Normal tension glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

